Though not statistically significant, breast cancer patients in the uterine leiomyoma group received more hormonal therapy for ER+ or PR+ (69.6%) than in the leiomyoma-free group (64.9%). The gene discussed is ESR1; the disease is uterine corpus leiomyoma.